Name (Synonyms) | Correlation | |
---|---|---|
drug1461 | Mefloquine + azithromycin + / - tocilizumab Wiki | 1.00 |
drug1091 | Hydroxychloroquine + azithromycin + / - tocilizumab Wiki | 1.00 |
drug1086 | Hydroxychloroquine Wiki | 0.10 |
There is one clinical trial.
Study of the effectiveness and safety of the drug Mefloquine, tablets 250 mg, produced by FSUE "SPC" Farmzaschita " FMBA of Russia (Russia), in comparison with the drug Hydroxychloroquine, tablets 200 mg, for the treatment of patients with coronavirus infection, in the "off-label" mode, to make a decision on the possibility of expanding the indications for use.
Description: The number of patients with development of respiratory failure requiring transfer to the ICU.
Measure: 1st primary endpoint for group 1 Time: up to 10 daysDescription: The period of clinical recovery.
Measure: 2nd primary endpoint for group 1 Time: up to 10 daysDescription: The period of clinical recovery.
Measure: 1st primary endpoint for group 2 Time: up to 10 daysDescription: Frequency of fatal outcomes associated with coronavirus infection disease (COVID19)
Measure: 2nd primary endpoint for group 2 Time: through study completion, an average of 3 monthsDescription: A change in viral load by conducting PCR assay through different timeframes
Measure: 1st secondary endpoint for group 1 Time: on days 5 and 10Description: Frequency of clinical cure on day 10 from the start of therapy
Measure: 2nd secondary endpoint for group 1 Time: on day 10Description: The retention time of the reaction temperature from the start of the treatment.
Measure: 3d secondary endpoint for group 1 Time: up to 10 daysDescription: Concentration of C-reactive protein in blood plasma.
Measure: 4th secondary endpoint for group 1 Time: up to 10 daysDescription: Respiratory index.
Measure: 5th secondary endpoint for group 1 Time: up to 10 daysDescription: Frequency appearance unwanted phenomena and serious unwanted phenomena
Measure: 6th secondary endpoint for group 1 Time: up to 10 daysDescription: A change in viral load by conducting PCR assay through different timeframes
Measure: 1st secondary endpoint for group 2 Time: on days 5 and 10Description: Respiratory index.
Measure: 2nd secondary endpoint for group 2 Time: up to 10 daysDescription: The retention time of the reaction temperature from the start of treatment.
Measure: 3d secondary endpoint for group 2 Time: up to 10 daysDescription: Concentration of C-reactive protein in blood plasma.
Measure: 4th secondary endpoint for group 2 Time: up to 10 daysDescription: Number of patients required transition to alternative therapy schedule
Measure: 5th secondary endpoint for group 2 Time: up to 10 daysDescription: Frequency of adverse events and serious adverse events
Measure: 6th secondary endpoint for group 2 Time: up to 10 days